| Code | CSB-RA055668MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to CRB-601, targeting transforming growth factor beta (TGF-β), a multifunctional cytokine that regulates cell proliferation, differentiation, immune responses, and extracellular matrix production. TGF-β plays a critical role in tissue homeostasis and wound healing under normal physiological conditions. However, dysregulated TGF-β signaling is implicated in numerous pathological processes, including fibrotic diseases, tumor progression, metastasis, and immune evasion in cancer. Elevated TGF-β expression creates an immunosuppressive tumor microenvironment and promotes epithelial-to-mesenchymal transition, making it an important therapeutic target in oncology and fibrosis research.
CRB-601 represents a reference antibody designed to neutralize TGF-β activity, providing researchers with a valuable tool for investigating TGF-β-mediated pathways. This biosimilar antibody enables studies examining TGF-β's role in cancer biology, immunology, fibrosis, and developmental biology. It is suitable for researchers exploring TGF-β signaling mechanisms, evaluating potential therapeutic interventions, and understanding disease pathogenesis associated with aberrant TGF-β activity.
There are currently no reviews for this product.